Flupen

# Flupen ## Overview - **Classification**: Novel Fluoroquinolone Antibiotic. - **Mechanism**: Inhibits bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA replication, transcription, repair, and recombination, leading to bacterial cell death. ## Primary Indications 1. **Complicated Urinary Tract Infections (cUTI)** - Including pyelonephritis. 2. **Community-Acquired Pneumonia (CAP)** - Due to susceptible organisms. 3. **Skin and Soft Tissue Infections (SSTI)** - Uncomplicated and complicated. ## Adult Dosing ### Standard Dosing **Complicated Urinary Tract Infections (cUTI)** - **Dose**: **500 mg** - **Frequency**: Once daily (**q24h**) - **Route**: Oral (PO) or Intravenous (IV) - **Duration**: 7-14 days, depending on severity and pathogen. **Community-Acquired Pneumonia (CAP) / Skin and Soft Tissue Infections (SSTI)** - **Dose**: **750 mg** - **Frequency**: Once daily (**q24h**) - **Route**: Oral (PO) or Intravenous (IV) - **Duration**: 5-10 days for CAP; 7-14 days for SSTI. ### Dose Adjustments - **Renal Impairment**: - **CrCl 30-50 mL/min**: **500 mg** q48h (for 500 mg usual dose), **750 mg** q48h (for 750 mg usual dose). - **CrCl <30 mL/min**: **250 mg** q24h (for 500 mg usual dose), **375 mg** q24h (for 750 mg usual dose). - **Hemodialysis/CAPD**: Administer dose after dialysis on dialysis days. - **Hepatic Impairment**: No dose adjustment typically required. - **Elderly Patients**: Monitor closely for QTc prolongation and tendon-related adverse events. ## Pediatric Dosing ### Neonates (0-28 days) - **Not Recommended**: Due to insufficient safety data and potential for musculoskeletal damage. - **Special Notes**: Use only in life-threatening situations where no alternative exists and benefits outweigh risks. ### Infants (1-12 months) - **Not Recommended**: Limited data, high risk of irreversible musculoskeletal adverse events. - **Special Notes**: Reserve for severe, multi-drug resistant infections with no other viable options. ### Children (1-12 years) - **Indication**: For severe, resistant infections (e.g., cUTI, complicated intra-abdominal) when alternative treatments are ineffective or contraindicated. - **Dose**: **10 mg/kg** - **Frequency**: Once daily (**q24h**) - **Maximum**: **500 mg/dose** - **Special Notes**: Monitor closely for joint pain, swelling, or gait abnormalities. ### Adolescents (13-18 years) - **Indication**: For severe, resistant infections similar to adult indications, especially when alternative agents are unsuitable. - **Dose**: **10 mg/kg** - **Frequency**: Once daily (**q24h**) - **Maximum**: **750 mg/dose** (similar to adult maximum dose). - **Special Notes**: Consider adult dosing if weight is >50 kg. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to **Flupen** or other quinolones. - **Absolute**: History of tendon disorders (e.g., tendon rupture) associated with quinolone use. - **Absolute**: Concomitant use with tizanidine. - **Relative**: Myasthenia gravis exacerbation, known QTc prolongation, uncorrected hypokalemia/hypomagnesemia. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, diarrhea, headache, dizziness. - **Common (1-10%)**: Insomnia, rash, abdominal pain, constipation. - **Serious but Rare**: Tendon rupture, peripheral neuropathy, QTc prolongation/arrhythmias, *Clostridioides difficile*-associated diarrhea (CDAD), severe hypoglycemia (especially in diabetics), aortic aneurysm rupture. ### Key Drug Interactions - **Antacids/Multivitamins (Mg, Al, Ca, Fe, Zn)**: Reduced **Flupen** absorption. Separate administration by at least **2 hours before** or **4 hours after**. - **Warfarin**: Increased INR. Monitor PT/INR frequently when co-administered. - **Corticosteroids**: Increased risk of tendon rupture. Use with extreme caution. - **QTc-prolonging drugs (e.g., Class IA/III antiarrhythmics, tricyclic antidepressants)**: Increased risk of QTc prolongation. Avoid co-administration if possible. ## Monitoring & Follow-up - **Before Treatment**: Obtain baseline renal function (CrCl), consider ECG if cardiac risk factors or concomitant QTc-prolonging drugs. - **During Treatment**: Monitor renal function in renally impaired patients. Observe for signs/symptoms of tendonitis/rupture, new-onset neuropathy, or blood glucose abnormalities (especially in diabetics). - **Clinical Signs**: Watch for new pain/swelling (especially heel/shoulder), numbness/tingling, muscle weakness, severe or persistent diarrhea, palpitations, or fainting. ## Clinical Pearls - 💡 **Tip 1**: Administer **Flupen** with a full glass of water to ensure adequate hydration and drug delivery. - 💡 **Tip 2**: Advise patients to avoid excessive sun exposure or artificial UV light due to photosensitivity risk. - 💡 **Tip 3**: Counsel patients to **immediately stop** **Flupen** and seek medical attention if they experience pain, swelling, or inflammation of a tendon, or any new or worsening neurological symptoms (e.g., numbness, tingling). > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.